# Synaptogenix Inc. (SNPX)

Source: https://www.quantisnow.com/company/SNPX
Generated: 2026-11-14T03:01:15.060Z

- Ticker: SNPX
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- Website: synaptogen.com

## About

Synaptogenix, Inc. operates as a biopharmaceutical company. It focuses on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and niemann-pick type C disease. It has licensing agreements with Stanford University; Icahn School of Medicine; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is based in New York, New York.

## Latest SNPX news and filings

- 2025-07-07 20:49 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Synaptogenix Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-synaptogenix-inc-6112926)
- 2025-07-02 20:07 UTC [SEC Form 4] [Director Singer William S. was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 700% to 10,566 units (SEC Form 4)](https://www.quantisnow.com/insight/director-singer-william-s-was-granted-15410-shares-and-covered-6108179)
- 2025-07-02 20:06 UTC [SEC Form 4] [Chief Financial Officer Weinstein Robert was granted 15,410 shares and covered exercise/tax liability with 6,164 shares, increasing direct ownership by 696% to 10,574 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-weinstein-robert-was-granted-15410-shares-and-6108174)
- 2025-07-02 20:06 UTC [SEC Form 4] [Executive Chairman Silverman Joshua was granted 41,919 shares and covered exercise/tax liability with 16,768 shares, increasing direct ownership by 1,644% to 26,681 units (SEC Form 4)](https://www.quantisnow.com/insight/executive-chairman-silverman-joshua-was-granted-41919-shares-and-covered-6108160)
- 2025-07-02 20:05 UTC [SEC Form 4] [Director Schechter Jonathan was granted 21,575 shares and covered exercise/tax liability with 8,630 shares, increasing direct ownership by 1,188% to 14,035 units (SEC Form 4)](https://www.quantisnow.com/insight/director-schechter-jonathan-was-granted-21575-shares-and-covered-exercisetax-6108148)
- 2025-07-02 20:05 UTC [SEC Form 4] [Director Bernstein Bruce covered exercise/tax liability with 9,863 shares and was granted 24,657 shares, increasing direct ownership by 1,341% to 15,897 units (SEC Form 4)](https://www.quantisnow.com/insight/director-bernstein-bruce-covered-exercisetax-liability-with-9863-shares-and-6108131)
- 2025-07-02 20:05 UTC [SEC Form 4] [Chief Medical Officer Tuchman Alan J was granted 4,315 shares and covered exercise/tax liability with 1,726 shares, increasing direct ownership by 196% to 3,909 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-tuchman-alan-j-was-granted-4315-shares-6108101)
- 2025-07-01 13:15 UTC [TAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open Today](https://www.quantisnow.com/insight/tao-synergies-formerly-synaptogenix-begins-trading-under-new-nasdaq-stock-6105192)
- 2025-06-27 20:02 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Synaptogenix Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-synaptogenix-inc-6101726)
- 2025-06-27 20:00 UTC [SEC Form 8-K] [Synaptogenix Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/synaptogenix-inc-filed-sec-form-8-k-leadership-update-regulation-fd-6101709)
- 2025-06-26 13:15 UTC [Synaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury Strategy](https://www.quantisnow.com/insight/synaptogenix-announces-name-change-to-tao-synergies-and-new-ticker-6100058)
- 2025-06-24 20:37 UTC [SEC Form 8-K] [Synaptogenix Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/synaptogenix-inc-filed-sec-form-8-k-regulation-fd-disclosure-other-6097548)
- 2025-06-24 13:15 UTC [Leadership Update] [Synaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking](https://www.quantisnow.com/insight/synaptogenix-announces-initial-tao-acquisition-under-crypto-treasury-strategy-appoints-6096894)
- 2025-06-23 20:05 UTC [SEC Form D] [SEC Form D filed by Synaptogenix Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-synaptogenix-inc-6095452)
- 2025-06-09 13:01 UTC [SEC Form 8-K] [Synaptogenix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits](https://www.quantisnow.com/insight/synaptogenix-inc-filed-sec-form-8-k-entry-into-a-material-6077830)
- 2025-06-09 13:00 UTC [Leadership Update] [Synaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI Token](https://www.quantisnow.com/insight/synaptogenix-appoints-crypto-expert-to-lead-digital-asset-treasury-strategy-6077815)
- 2025-05-15 20:15 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Synaptogenix Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-synaptogenix-inc-6042568)
- 2025-04-07 21:01 UTC [SEC Form 4] [SEC Form 4 filed by Director Singer William S.](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-singer-william-s-5980046)
- 2025-04-07 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Schechter Jonathan](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-schechter-jonathan-5980043)
- 2025-04-07 21:00 UTC [SEC Form 4] [SEC Form 4 filed by Director Bernstein Bruce](https://www.quantisnow.com/insight/sec-form-4-filed-by-director-bernstein-bruce-5980036)
- 2025-03-27 21:23 UTC [SEC Form 10-K] [SEC Form 10-K filed by Synaptogenix Inc.](https://www.quantisnow.com/insight/sec-form-10-k-filed-by-synaptogenix-inc-5963699)
- 2024-12-20 14:21 UTC [SEC Form 8-K] [Synaptogenix Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/synaptogenix-inc-filed-sec-form-8-k-other-events-financial-statements-5821641)
- 2024-12-20 14:15 UTC [Synaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet Strength](https://www.quantisnow.com/insight/synaptogenix-board-of-directors-forms-special-committee-to-explore-value-5821629)
- 2024-12-06 22:06 UTC [SEC Form 8-K] [Synaptogenix Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits](https://www.quantisnow.com/insight/synaptogenix-inc-filed-sec-form-8-k-submission-of-matters-to-5804118)
- 2024-11-20 01:22 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Synaptogenix Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-synaptogenix-inc-5784076)
- 2024-11-12 22:00 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Synaptogenix Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-synaptogenix-inc-5768770)
- 2024-11-07 13:54 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Synaptogenix Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-synaptogenix-inc-5757995)
- 2024-10-28 20:00 UTC [SEC Form PRE 14A] [SEC Form PRE 14A filed by Synaptogenix Inc.](https://www.quantisnow.com/insight/sec-form-pre-14a-filed-by-synaptogenix-inc-5739872)
- 2024-10-22 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Synaptogenix Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-synaptogenix-inc-5732423)
- 2024-10-10 21:11 UTC [SEC Form S-3] [SEC Form S-3 filed by Synaptogenix Inc.](https://www.quantisnow.com/insight/sec-form-s-3-filed-by-synaptogenix-inc-5722707)
- 2024-10-04 20:30 UTC [SEC Form 8-K] [Synaptogenix Inc. filed SEC Form 8-K: Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits](https://www.quantisnow.com/insight/synaptogenix-inc-filed-sec-form-8-k-changes-in-registrants-certifying-5717192)
- 2024-09-23 21:04 UTC [SEC Form D] [SEC Form D filed by Synaptogenix Inc.](https://www.quantisnow.com/insight/sec-form-d-filed-by-synaptogenix-inc-5702372)
- 2024-09-13 20:54 UTC [SEC Form 8-K] [Synaptogenix Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/synaptogenix-inc-filed-sec-form-8-k-amendments-to-articles-of-5693710)
- 2024-09-11 13:00 UTC [SEC Form 8-K] [Synaptogenix Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/synaptogenix-inc-filed-sec-form-8-k-entry-into-a-material-5690117)
- 2024-09-11 13:00 UTC [Public Offering] [Synaptogenix Announces $5.0 Million Financing](https://www.quantisnow.com/insight/synaptogenix-announces-50-million-financing-5690115)
- 2024-09-09 21:00 UTC [SEC Form 8-K] [Synaptogenix Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits](https://www.quantisnow.com/insight/synaptogenix-inc-filed-sec-form-8-k-amendments-to-articles-of-5687717)
- 2024-08-14 20:30 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Synaptogenix Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-synaptogenix-inc-5659567)
- 2024-07-18 13:05 UTC [Market Chatter] [Synaptogenix Announces Collaboration With LSU Health New Orleans For Pre-Clinical Testing Of PUFA Analogs For Spinal Cord Injury](https://www.quantisnow.com/insight/synaptogenix-announces-collaboration-with-lsu-health-new-orleans-for-pre-clinical-5614964)
- 2024-07-18 13:00 UTC [Synaptogenix Announces New Collaboration with LSU Health New Orleans for Study of Proprietary Analogs in Spinal Cord Injury](https://www.quantisnow.com/insight/synaptogenix-announces-new-collaboration-with-lsu-health-new-orleans-for-5614932)
- 2024-07-11 13:08 UTC [Market Chatter] [Maxim Group Upgrades Synaptogenix to Buy, Announces $14 Price Target](https://www.quantisnow.com/insight/maxim-group-upgrades-synaptogenix-to-buy-announces-14-price-target-5603627)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/SNPX
- Earnings history: https://www.quantisnow.com/earnings/SNPX
- Dividend history: https://www.quantisnow.com/dividends/SNPX
- Insider transactions: https://www.quantisnow.com/insiders/SNPX
- Options chain: https://www.quantisnow.com/options/SNPX
- SEC 8-K filings only: https://www.quantisnow.com/company/SNPX/8-k
- RSS and alerts for SNPX: https://www.quantisnow.com/docs/rss-feeds.md